Skip to main content
. 2022 Jan 1;14(1):210. doi: 10.3390/cancers14010210

Figure 2.

Figure 2

Figure 2

Figure 2

Sequential eribulin and abemaciclib treatment results in enhanced cell growth inhibition. (A) The viability of palbociclib-sensitive HR-positive cells (MCF7 and T47D), palbociclib-resistant HR-positive cells (MCF7-PR and T47D-PR), and TNBC (MDA-MB-231) cells after eribulin or abemaciclib treatment at different concentrations for 48 h were assessed by MTT. IC50 values were calculated using CompuSyn. The data represent the mean ± standard deviation of four replicates. (B) Cells were treated with increasing concentrations of eribulin and abemaciclib combinations at a fixed ratio for 48 h. Eribulin was given first, and abemaciclib was then given sequentially without a time gap, and cell viability was determined by MTT assay. (C) Cells were treated with increasing concentrations of eribulin and abemaciclib combinations at a fixed ratio for 48 h. Both drugs were given simultaneously, and the cell viability was determined by MTT assay. The CI was calculated by the Chou–Talalay method. CI < 1, CI > 1, and CI = 1 indicate synergism, antagonism, and additive effect, respectively. HR Hormone receptor, TNBC triple-negative breast cancer.